SoC Clinical Trials

5 actively recruiting trials across 3 locations

No change since May 2026

Pipeline

Phase 2: 3Phase 1/2: 2

Top Sponsors

Universitaire Ziekenhuizen KU Leuven1
UNC Lineberger Comprehensive Cancer Center1
Guangdong Association of Clinical Trials1
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.1
BioNTech SE1

Indications

Cancer5
Lung Cancer3
Breast Cancer3
Triple Negative Breast Cancer (TNBC), Early Setting1
Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma1

Other2 trials

LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer

Phase 2

Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment

Phase 2

Los Angeles, California1 trial

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

USC Norris Comprehensive Cancer Center

Phase 1/2

Stanford, California1 trial

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

Stanford Cancer Institute

Phase 1/2

Rochester, Minnesota1 trial

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Mayo Clinic

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.